Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | PRKACA | P17612 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | PRKACG | P22612 | 1/20 | 0.30 |
| ▸ | PRKACB | P22694 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22224583 | 1.00 | ADORA3 (0.36) | ADORA3ADORA1ADORA2BADORA2ACDK1 | |
| SCHEMBL20272115 | 1.00 | ADORA3 (0.36) | ADORA3ADORA1ADORA2BADORA2ACDK1 | |
| SCHEMBL22889510 | 0.91 | ADORA3 (0.34) | ADORA3ADORA1ADORA2BADORA2A | |
| SCHEMBL22889172 | 0.89 | — | — | |
| SCHEMBL22889473 | 0.87 | — | — | |
| SCHEMBL22889225 | 0.85 | CCNE2 (0.31) | CDK2 | |
| SCHEMBL22889469 | 0.84 | ADORA3 (0.34) | ADORA3ADORA1ADORA2BCDK1PRKACA | |
| SCHEMBL19833093 | 0.84 | ADORA3 (0.38) | ADORA3ADORA1ADORA2BADORA2ACDK1 | |
| SCHEMBL19644850 | 0.84 | ADORA3 (0.38) | ADORA3ADORA1ADORA2BADORA2ACDK1 | |
| SCHEMBL23761053 | 0.80 | ADORA3 (0.38) | ADORA3ADORA1ADORA2BADORA2ACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | Atea Pharmaceuticals, Inc. (US) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222442-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | ADORA3 59/4885ADORA1 115/4885ADORA2B 84/4885 |
| US-20230017958-A1 | 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT | NSUN2, ADAR, NSUN3 | ADORA3 59/4885ADORA1 115/4885ADORA2B 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.